BioHarvest Sciences (NASDAQ:BHST - Get Free Report) is expected to be issuing its Q4 2024 quarterly earnings data before the market opens on Tuesday, April 29th. Analysts expect the company to announce earnings of ($0.12) per share and revenue of $7.80 million for the quarter.
BioHarvest Sciences (NASDAQ:BHST - Get Free Report) last posted its quarterly earnings data on Monday, March 31st. The company reported ($0.17) earnings per share for the quarter, missing the consensus estimate of ($0.12) by ($0.05). The company had revenue of $7.17 million for the quarter, compared to analysts' expectations of $7.24 million. On average, analysts expect BioHarvest Sciences to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.
BioHarvest Sciences Price Performance
Shares of BHST opened at $5.88 on Wednesday. The company has a fifty day moving average price of $5.73. The company has a market cap of $96.58 million, a price-to-earnings ratio of -4.71 and a beta of 0.84. BioHarvest Sciences has a 52 week low of $5.50 and a 52 week high of $7.38.
Analyst Ratings Changes
Separately, HC Wainwright reiterated a "buy" rating and issued a $14.00 price target on shares of BioHarvest Sciences in a report on Tuesday, April 8th.
View Our Latest Report on BHST
About BioHarvest Sciences
(
Get Free Report)
BioHarvest Sciences Inc is a biotech firm. It focused on leveraging its botanical synthesis technology to develop science-based and clinically proven therapeutic solutions, within business verticals nutraceutical health and wellness products such as dietary supplements and development of plant cell-based Active Pharmaceutical Ingredients which focus on specific medical indications.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider BioHarvest Sciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and BioHarvest Sciences wasn't on the list.
While BioHarvest Sciences currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Almost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
